NCT05308446Source recordAI-normalized
Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
AI analysis
Indication: Metastatic Colon Adenocarcinoma
Modality: monoclonal antibody
Target: Cetuximab, Encorafenib, Nivolumab
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Jun 03, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Condition normalized: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Cetuximab, Encorafenib, Nivolumab
Target normalized: Cetuximab, Encorafenib, Nivolumab
NCT01200758Source recordAI-normalized
A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV
This two-stage, multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, efficacy and safety of rituximab SC versus rituximab IV in participants with previously untreated follicular non-Hodgkin's lymphoma. Participants will be randomized to receive 375 milligrams per meter square (mg/m\^2) rituximab as IV infusion or 1400 milligrams (mg) rituximab SC. In addition, participants will receive standard chemotherapy. Participants who achieved a complete or partial response (PR) after 8 treatment cycles, will receive maintenance treatment for a further maximum number of 12 cycles. Maintenance treatment cycles will be repeated every 8 weeks. This is a two-stage study. Stage 1 was designed to confirm the chosen rituximab SC dose resulting in comparable rituximab serum Ctrough levels compared with rituximab IV, when given as part of induction treatment every 3 weeks. Enrollment for Stage 2 started after the rituximab SC dose was established in Stage 1. Stage 2 aimed to further investigate the efficacy and safety of rituximab SC compared with rituximab IV. The anticipated time on study treatment is 96 weeks.
AI analysis
Indication: Non-Hodgkin's Lymphoma
Modality: monoclonal antibody
Target: Rituximab SC, Rituximab IV, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Nov 27, 2018
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Non-Hodgkin's Lymphoma
Condition normalized: Non-Hodgkin's Lymphoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Rituximab SC, Rituximab IV, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone
Target normalized: Rituximab SC, Rituximab IV, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone
NCT00107380Source recordAI-normalized
Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving a radiolabeled monoclonal antibody together with rituximab and combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving iodine I 131 tositumomab together with rituximab and combination chemotherapy works in treating older patients with stage II, stage III, or stage IV B-cell non-Hodgkin's lymphoma.
AI analysis
Indication: Lymphoma
Modality: monoclonal antibody
Target: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Sponsor: SWOG Cancer Research Network
Source URL: ClinicalTrials.gov
Source updated: Mar 07, 2016
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Lymphoma
Condition normalized: Lymphoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Target normalized: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
NCT06191744Source recordAI-normalized
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world. Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \[G-CHOP\]/ R-CHOP or G and IV infusion of bendamustine (Benda) \[G-Benda\]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
AI analysis
Indication: Follicular Lymphoma (FL)
Modality: monoclonal antibody
Target: Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Sponsor: Genmab
Source URL: ClinicalTrials.gov
Source updated: Jun 02, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Follicular Lymphoma (FL)
Condition normalized: Follicular Lymphoma (FL)
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Target normalized: Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
NCT00070447Source recordAI-normalized
Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients With Previously Untreated Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as prednisone, cyclophosphamide, doxorubicin, and vincristine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab and combination chemotherapy together with yttrium Y 90 ibritumomab tiuxetan works in treating patients with previously untreated mantle cell lymphoma.
AI analysis
Indication: Lymphoma
Modality: monoclonal antibody
Target: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, yttrium Y 90 ibritumomab tiuxetan
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Jan 28, 2014
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Lymphoma
Condition normalized: Lymphoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, yttrium Y 90 ibritumomab tiuxetan
Target normalized: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, yttrium Y 90 ibritumomab tiuxetan
NCT00544219Source recordAI-normalized
Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study
RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone.
AI analysis
Indication: Lymphoma
Modality: monoclonal antibody
Target: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography
Sponsor: Swiss Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: May 15, 2019
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Lymphoma
Condition normalized: Lymphoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography
Target normalized: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography
NCT03677141Source recordAI-normalized
A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).
AI analysis
Indication: B-cell Non-Hodgkin Lymphoma
Modality: monoclonal antibody
Target: Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Dec 18, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: B-cell Non-Hodgkin Lymphoma
Condition normalized: B-cell Non-Hodgkin Lymphoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Target normalized: Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
NCT06095427Source recordAI-normalized
A Randomized, Double Blind, Three-Arm, Parallel Group, Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US Prolia and EU Prolia by Single-Dose Subcutaneous Injection
This trial is a randomized, double-blind, three-arm, parallel-group, pharmacokinetic study. The purpose of this study is to demonstrate pharmacokinetic (PK) similarity and to compare safety, immunogenicity and pharmacodynamics (PD) between the test product L06006 and the reference products US-Prolia and EU-Prolia in healthy male subjects. A total of 300 healthy male subjects aged 28 to 65 years (both inclusive) will be randomized 1:1:1 to receive a single subcutaneous (s.c.) injection of either LY06006 or US-Prolia or EU-Prolia on Day 1 and then be followed for 36 weeks.
AI analysis
Indication: Healthy
Modality: monoclonal antibody
Target: LY06006 (Denosumab Biosimilar), US-Prolia (Denosumab), EU-Prolia
Sponsor: Luye Pharma Group Ltd.
Source URL: ClinicalTrials.gov
Source updated: Oct 23, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Healthy
Condition normalized: Healthy
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: LY06006 (Denosumab Biosimilar), US-Prolia (Denosumab), EU-Prolia
Target normalized: LY06006 (Denosumab Biosimilar), US-Prolia (Denosumab), EU-Prolia
NCT03839459Source recordAI-normalized
Denosumab for Smoldering Multiple Myeloma
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.
AI analysis
Indication: Smoldering Multiple Myeloma
Modality: monoclonal antibody
Target: Denosumab
Sponsor: University of Rochester
Source URL: ClinicalTrials.gov
Source updated: Jan 28, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Smoldering Multiple Myeloma
Condition normalized: Smoldering Multiple Myeloma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab
Target normalized: Denosumab
NCT01575873Source recordAI-normalized
A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals
This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
AI analysis
Indication: Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Modality: monoclonal antibody
Target: Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Jul 27, 2018
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Condition normalized: Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Target normalized: Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
NCT02053753Source recordAI-normalized
A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product
To evaluate the bioequivalence based on pharmacokinetics (PK) of a single 120 mg subcutaneous dose of denosumab administered to healthy volunteers using denosumab CP4 or denosumab CP2 drug products.
AI analysis
Indication: Healthy Volunteer
Modality: monoclonal antibody
Target: Denosumab CP4, Denosumab CP2
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Dec 29, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Healthy Volunteer
Condition normalized: Healthy Volunteer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab CP4, Denosumab CP2
Target normalized: Denosumab CP4, Denosumab CP2
NCT05419050Source recordAI-normalized
A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
Background: Fibrous dysplasia (FD) is a disease that affects the bones. It causes bone lesions that can become weak and lead to fractures, deformity, and nerve injuries. FD bone lesions begin to develop soon after birth and grow during childhood. The lesions stop growing in adults but can still cause disability. Researchers want to find ways to stop the growth of FD bone lesions. Objective: To test a study drug (denosumab) in children with FD. Eligibility: Children aged 4 to 14 years with FD and who are also enrolled in the Screening and Natural History protocol (98-D-0145). Design: Participants will have a screening visit at the NIH clinic or by telehealth. Their medical history will be reviewed. Participants will stay overnight in the hospital 4 times in 76 weeks. Each stay will last 5 to 7 nights. Participants will also visit a local lab for blood and urine tests every 4 weeks during the study. Participants will receive denosumab once every 4 weeks for 48 weeks. The medication is given as a shot injected under the skin using a small needle. Some injections may be performed at home by a caregiver. The caregiver will receive training for this procedure. Participants will undergo many tests that may be repeated throughout the study. They will have a dental exam. They will have tests of their strength and ability to move freely. They will have x-rays and other scans to get pictures of their bones. Participants will be given another medicine that is administered through a needle in the arm over 30 minutes.
AI analysis
Indication: Fibrous Dysplasia
Modality: monoclonal antibody
Target: denosumab
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Source URL: ClinicalTrials.gov
Source updated: Jan 20, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Fibrous Dysplasia
Condition normalized: Fibrous Dysplasia
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: denosumab
Target normalized: denosumab
NCT04608630Source recordAI-normalized
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults - A Randomised Controlled Trial
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours. 450 women aged 50 years or older and men aged 70 years or older, admitted to intensive care for greater than 24 hours will be recruited into the study from participating study centres.
AI analysis
Indication: Critical Illness
Modality: monoclonal antibody
Target: Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Sodium Chloride 0.9% Injection
Sponsor: Australian and New Zealand Intensive Care Research Centre
Source URL: ClinicalTrials.gov
Source updated: Mar 04, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Critical Illness, Osteoporosis
Condition normalized: Critical Illness, Osteoporosis
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Sodium Chloride 0.9% Injection
Target normalized: Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Sodium Chloride 0.9% Injection
NCT01464931Source recordAI-normalized
An Open-label Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg Administered Subcutaneously in Subjects With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis
AI analysis
Indication: Renal Impairment
Modality: monoclonal antibody
Target: Denosumab
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Feb 19, 2016
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Renal Impairment
Condition normalized: Renal Impairment
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab
Target normalized: Denosumab
NCT06361355Source recordAI-normalized
A Randomized, Double-blind, Parallel Controlled, Phase I Study, Comparing the PK, PD, Safety, and Immunogenicity of Post-change CMAB807and Prolia in Healthy Chinese Subjects
This is a randomized, double-blinded, parallel-controlled Phase I study of CMAB807 administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807 Post-change in Manufacturing Site, versus Prolia #Denosumab# in healthy male subjects after a single dose
AI analysis
Indication: Healthy Volunteers
Modality: monoclonal antibody
Target: Post-change CMAB807, Prolia
Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
Source URL: ClinicalTrials.gov
Source updated: Nov 07, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Healthy Volunteers
Condition normalized: Healthy Volunteers
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Post-change CMAB807, Prolia
Target normalized: Post-change CMAB807, Prolia
NCT05777109Source recordAI-normalized
A Dual-center, Randomized, Double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, Pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults
A Dual-center , Randomized, double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults
AI analysis
Indication: Healthy
Modality: monoclonal antibody
Target: HS-20090, Xgeva®
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Aug 23, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Healthy
Condition normalized: Healthy
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: HS-20090, Xgeva®
Target normalized: HS-20090, Xgeva®
NCT03005678Source recordAI-normalized
Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial
A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: Denosumab, Alendronate
Sponsor: Tuen Mun Hospital
Source URL: ClinicalTrials.gov
Source updated: Feb 12, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab, Alendronate
Target normalized: Denosumab, Alendronate
NCT05010590Source recordAI-normalized
Anabolic Therapy in Postmenopausal Osteoporosis
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
AI analysis
Indication: Postmenopausal Osteoporosis
Modality: monoclonal antibody
Target: Romosozumab, Denosumab
Sponsor: Massachusetts General Hospital
Source URL: ClinicalTrials.gov
Source updated: Apr 15, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Postmenopausal Osteoporosis
Condition normalized: Postmenopausal Osteoporosis
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Romosozumab, Denosumab
Target normalized: Romosozumab, Denosumab
NCT01358669Source recordAI-normalized
Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip
Although hip replacement surgery is a successful way of dealing with the pain and immobility caused by hip arthritis, 10% of the hip replacements carried out in the UK fail within 10 years. The main reason for this is the development periprosthetic osteolysis, that is, loss of bone around the site of the hip replacement. The osteolysis is thought to be due to the small particles of debris worn from the surfaces of the hip implant. These particles cause a reaction in the blood cells around the joint which in turn affects bone cells and leads to a loss of bone around the implant. The joint implant will then eventually become loose and unstable, a condition known as aseptic loosening. At present the only way to treat aseptic loosening is to have another operation to secure the hip joint, known as revision surgery. Revision surgery is not always successful and exposes the patient to the risk of major surgery. In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant. We will recruit patients who have been listed for revision surgery. One group of patients will be given a single dose of denosumab; another group will be given a placebo (dummy drug). At the time of the revision surgery a small sample of the bone from around the hip replacement will be taken and examined under the microscope. Comparisons will be made between the patients having the denosumab and those having placebo to find out whether the denosumab is having a beneficial effect on the bone surfaces. If successful, this study will lead to further studies to develop the use of denosumab to prevent aseptic loosening.
AI analysis
Indication: Revision Surgery of Total Hip Arthroplasty
Modality: monoclonal antibody
Target: Denosumab, Placebo
Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Source URL: ClinicalTrials.gov
Source updated: Aug 29, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Revision Surgery of Total Hip Arthroplasty
Condition normalized: Revision Surgery of Total Hip Arthroplasty
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab, Placebo
Target normalized: Denosumab, Placebo
NCT02049866Source recordAI-normalized
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
The purpose of this research study is to evaluate antiresorptive therapy with denosumab (Prolia) for prevention of bone loss after stopping teriparatide (TPTD) in premenopausal women with idiopathic osteoporosis. Premenopausal women who have received TPTD in the FDA Orphan Diseases Program-funded trial, "A Phase 2 Study of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women" (NCT01440803) may be eligible to participate in the current study, a 36-month open-label pilot study of denosumab (Prolia®, 60mg subcutaneous (SC) every 6 months). The goals of the study are to estimate the effects of denosumab on central and peripheral, as well as trabecular and cortical, bone mass and microstructure and to obtain preliminary data to inform the design of a future randomized study. This study presents the first opportunity to study the effects of denosumab after TPTD in this unique and severely affected group of young women. Funding Source: FDA Office of Orphan Products Development (OOPD).
AI analysis
Indication: Adult Idiopathic Generalized Osteoporosis
Modality: monoclonal antibody
Target: Denosumab
Sponsor: Elizabeth Shane
Source URL: ClinicalTrials.gov
Source updated: Dec 12, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Adult Idiopathic Generalized Osteoporosis
Condition normalized: Adult Idiopathic Generalized Osteoporosis
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab
Target normalized: Denosumab
NCT00321620Source recordAI-normalized
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
AI analysis
Indication: Bone Metastases
Modality: monoclonal antibody
Target: zoledronic acid, denosumab
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Aug 29, 2018
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Bone Metastases
Condition normalized: Bone Metastases
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: zoledronic acid, denosumab
Target normalized: zoledronic acid, denosumab
NCT00286091Source recordAI-normalized
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis at baseline.
AI analysis
Indication: Hormone Refractory Prostate Cancer
Modality: monoclonal antibody
Target: Denosumab, Placebo
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Oct 17, 2018
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Hormone Refractory Prostate Cancer
Condition normalized: Hormone Refractory Prostate Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab, Placebo
Target normalized: Denosumab, Placebo
NCT02352753Source recordAI-normalized
To Evaluate the Effect of Denosumab in Lumbar Spine Bone Mineral Density (BMD) Z-score at 12 Months, as Assessed by Dual-energy X-ray Absorptiometry (DXA), in Children 2 to 17 Years of Age (at the Time of Screening) on a 3-Month Dosing Regimen With OI
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: monoclonal antibody
Target: Denosumab
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Dec 28, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab
Target normalized: Denosumab
NCT05125809Source recordAI-normalized
An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-Controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects With Osteogenesis Imperfecta
The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: monoclonal antibody
Target: Setrusumab, Placebo
Sponsor: Ultragenyx Pharmaceutical Inc
Source URL: ClinicalTrials.gov
Source updated: Feb 25, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Setrusumab, Placebo
Target normalized: Setrusumab, Placebo
NCT04545554Source recordAI-normalized
An Open-label, Ascending Multiple-dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with Osteogenesis Imperfecta (OI).
AI analysis
Indication: Osteogenesis Imperfecta
Modality: monoclonal antibody
Target: Romosozumab, Calcium, Vitamin D
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Apr 15, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Romosozumab, Calcium, Vitamin D
Target normalized: Romosozumab, Calcium, Vitamin D
NCT05312697Source recordAI-normalized
A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
The primary objective of the study is to evaluate bone mineral density (BMD) after 12 months of retreatment with monthly setrusumab in adults with osteogenesis imperfecta (OI).
AI analysis
Indication: Osteogenesis Imperfecta
Modality: monoclonal antibody
Target: Setrusumab
Sponsor: Ultragenyx Pharmaceutical Inc
Source URL: ClinicalTrials.gov
Source updated: Jul 23, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Setrusumab
Target normalized: Setrusumab
NCT06508658Source recordAI-normalized
A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBCL will be enrolled in approximately 165 sites across the world. Participants in arm A will receive subcutaneous (SC) injections of epcoritamab plus oral lenalidomide capsules (E-Len) for up to 12 cycles (each cycle is 28 days). Participants in arm B will receive intravenously (IV) infused R-GemOx for up to 4 cycles (each cycle is 28 days). Participants in arm C will receive SC injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
AI analysis
Indication: Diffuse Large B-Cell Lymphoma
Modality: monoclonal antibody
Target: Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Sponsor: Genmab
Source URL: ClinicalTrials.gov
Source updated: Apr 08, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Diffuse Large B-Cell Lymphoma
Condition normalized: Diffuse Large B-Cell Lymphoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Target normalized: Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
NCT00576758Source recordAI-normalized
An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab \[GA101 (RO5072759)\] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma. Patients will be randomized to receive either GA101 or rituximab, given as four weekly infusions. At the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.
AI analysis
Indication: Non-Hodgkin's Lymphoma
Modality: monoclonal antibody
Target: obinutuzumab (RO5072759), rituximab
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Aug 19, 2014
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Non-Hodgkin's Lymphoma
Condition normalized: Non-Hodgkin's Lymphoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: obinutuzumab (RO5072759), rituximab
Target normalized: obinutuzumab (RO5072759), rituximab
NCT04324021Source recordAI-normalized
A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the most important negative prognostic factors in patients infected with sSARS-CoV-2. The objective of this study is to investigate new treatment options to reduce the number of patients requiring mechanical ventilation. This is intended to address the most urgent need to preserve the access to intensive care unit support to the lowest possible number of patients and may potentially reduce mortality.
AI analysis
Indication: SARS-CoV-2
Modality: monoclonal antibody
Target: Emapalumab, Anakinra
Sponsor: Swedish Orphan Biovitrum
Source URL: ClinicalTrials.gov
Source updated: Mar 10, 2022
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: SARS-CoV-2
Condition normalized: SARS-CoV-2
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Emapalumab, Anakinra
Target normalized: Emapalumab, Anakinra
NCT04900428Source recordAI-normalized
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19
This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.
AI analysis
Indication: Covid19
Modality: monoclonal antibody
Target: COVI-DROPS, Placebo
Sponsor: Sorrento Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Jan 30, 2023
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Covid19
Condition normalized: Covid19
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: COVI-DROPS, Placebo
Target normalized: COVI-DROPS, Placebo
NCT04738175Source recordAI-normalized
A Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19
Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV push.
AI analysis
Indication: Covid19
Modality: monoclonal antibody
Target: COVI-AMG, Placebo
Sponsor: Sorrento Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Feb 25, 2022
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Covid19
Condition normalized: Covid19
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: COVI-AMG, Placebo
Target normalized: COVI-AMG, Placebo
NCT03464136Source recordAI-normalized
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease
The purpose of this study is to compare the efficacy of treatment with ustekinumab or adalimumab in biologic naive participants with moderately-to-severely active Crohn's disease (CD) who have previously failed or were intolerant to conventional therapy (corticosteroids and/or immunomodulators, such as azathioprine, 6-mercaptopurine, or methotrexate), as measured by clinical remission at one year.
AI analysis
Indication: Crohn Disease
Modality: monoclonal antibody
Target: Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
Sponsor: Janssen Scientific Affairs, LLC
Source URL: ClinicalTrials.gov
Source updated: Apr 29, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Crohn Disease
Condition normalized: Crohn Disease
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
Target normalized: Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
NCT04454398Source recordAI-normalized
A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19
Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19
AI analysis
Indication: Covid-19
Modality: monoclonal antibody
Target: COVI-GUARD, Standard of Care, Placebo
Sponsor: Sorrento Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Jan 08, 2021
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Covid-19
Condition normalized: Covid-19
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: COVI-GUARD, Standard of Care, Placebo
Target normalized: COVI-GUARD, Standard of Care, Placebo
NCT07246863Source recordAI-normalized
Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).
AI analysis
Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Modality: monoclonal antibody
Target: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Sponsor: CatalYm GmbH
Source URL: ClinicalTrials.gov
Source updated: Jun 09, 2026
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Condition normalized: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Target normalized: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
NCT03312907Source recordAI-normalized
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety profile, by comparing subjects randomized to belimumab plus rituximab versus belimumab plus rituximab-placebo. Approximately 292 subjects will be randomized in a 1:2:1 ratio to 1 of 3 treatment arms; belimumab plus rituximab-placebo (Arm A, control), belimumab plus rituximab (Arm B, combination), or belimumab plus standard therapy (Arm C, reference). Belimumab will be administered as subcutaneous (SC) and rituximab-placebo or rituximab will be administered by intravenous (IV) infusions. The total duration of the study is for 104 weeks.
AI analysis
Indication: Systemic Lupus Erythematosus
Modality: monoclonal antibody
Target: Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Sponsor: GlaxoSmithKline
Source URL: ClinicalTrials.gov
Source updated: Feb 18, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Systemic Lupus Erythematosus
Condition normalized: Systemic Lupus Erythematosus
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Target normalized: Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
NCT04840758Source recordAI-normalized
A Prospective Single-arm Single-center Clinical Study：Assessment of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer (sMPLC)
The purpose of this study is to assess of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) combined with Sintilimab in early inoperable synchronous Multiple Primary Lung Cancer (sMPLC)
AI analysis
Indication: Multiple Primary Lung Cancer
Modality: monoclonal antibody
Target: Stereotactic Ablation Radiotherapy, Sintilimab
Sponsor: The First Affiliated Hospital of Xiamen University
Source URL: ClinicalTrials.gov
Source updated: Apr 12, 2021
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Multiple Primary Lung Cancer
Condition normalized: Multiple Primary Lung Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Stereotactic Ablation Radiotherapy, Sintilimab
Target normalized: Stereotactic Ablation Radiotherapy, Sintilimab
NCT03761914Source recordAI-normalized
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
AI analysis
Indication: Acute Myelogenous Leukemia
Modality: monoclonal antibody
Target: galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Sponsor: Sellas Life Sciences Group
Source URL: ClinicalTrials.gov
Source updated: Nov 19, 2024
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Condition normalized: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Target normalized: galinpepimut-S, pembrolizumab, Montanide, GM-CSF
NCT02481830Source recordAI-normalized
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
AI analysis
Indication: Lung Cancer
Modality: monoclonal antibody
Target: Nivolumab, Topotecan, Amrubicin
Sponsor: Bristol-Myers Squibb
Source URL: ClinicalTrials.gov
Source updated: Jul 27, 2023
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Lung Cancer
Condition normalized: Lung Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Nivolumab, Topotecan, Amrubicin
Target normalized: Nivolumab, Topotecan, Amrubicin
NCT03487263Source recordAI-normalized
A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses. Patients must be within 3 years of MND diagnosis and have adequate respiratory function. Safety, tolerability, immunogenicity, and PK/PD will be measured. To evaluate feasibility of the endpoints, additional endpoints of ALSFRS-R, respiratory function tests, disease biomarkers and patient-reported outcomes will be measured.
AI analysis
Indication: Motor Neuron Disease
Modality: monoclonal antibody
Target: IC14
Sponsor: Implicit Bioscience
Source URL: ClinicalTrials.gov
Source updated: Aug 20, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Condition normalized: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: IC14
Target normalized: IC14
NCT04675827Source recordAI-normalized
De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade
DECRESCENDO is a multicentre, open-label, dual-phase single-arm phase II de-escalation study evaluating neoadjuvant treatment with 12 administrations of weekly IV paclitaxel 80 mg/m2 (or IV docetaxel 75 mg/m2 every 3 weeks for 4 cycles) combined with subcutaneous (SC) fixed dose combination (FDC) of pertuzumab and trastuzumab (loading dose of 1200 mg pertuzumab and 600 mg trastuzumab, followed by 600 mg pertuzumab and 600 mg trastuzumab) every 3 weeks for 4 cycles. Surgery will be performed according to local guidelines in all subjects after neoadjuvant treatment. After surgery, subjects who achieve a pCR (defined as pT0/Tis pN0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Subjects with residual invasive disease will receive salvage adjuvant trastuzumab emtansine (T-DM1, 3.6 mg/kg, IV every 3 weeks) for 14 cycles. In subjects whose residual invasive disease is classified per RCB score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1. If histopathological analysis finds that the surgical specimen from a subject with residual disease is ER-positive and/or PR-positive, adjuvant endocrine therapy may be administered concomitantly with study treatment, at the investigator's discretion and according to local guidelines. Adjuvant radiotherapy will be mandatory after breast-conserving surgery, whereas it will be performed according to local guidelines after mastectomy, and it will be administered concomitantly with pertuzumab and trastuzumab FDC SC in subjects who achieve a pCR, and concomitantly with T-DM1 in subjects with residual invasive disease (after anthracycline-based chemotherapy in subjects assigned to receive this treatment).
AI analysis
Indication: HER2-positive Breast Cancer
Modality: monoclonal antibody
Target: Pertuzumab and tratuzumab fixed dose combination, Trastuzumab emtansine
Sponsor: Jules Bordet Institute
Source URL: ClinicalTrials.gov
Source updated: Dec 04, 2024
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
Condition normalized: HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Pertuzumab and tratuzumab fixed dose combination, Trastuzumab emtansine
Target normalized: Pertuzumab and tratuzumab fixed dose combination, Trastuzumab emtansine
NCT03529110Source recordAI-normalized
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
Sponsor: Daiichi Sankyo
Source URL: ClinicalTrials.gov
Source updated: Oct 21, 2025
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
Target normalized: Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
NCT01196052Source recordAI-normalized
A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Cancer
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive breast cancer. Patients received T-DM1 3.6 mg/kg intravenously on Day 1 of each 3-week cycle, for up to 17 cycles.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: Trastuzumab emtansine
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Oct 06, 2014
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Trastuzumab emtansine
Target normalized: Trastuzumab emtansine
NCT04620187Source recordAI-normalized
A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas
This clinical trial, sponsored by Dana-Farber Cancer Institute in collaboration with Genentech, investigates the safety and efficacy of Ado-trastuzumab emtansine (T-DM1) combined with standard chemoradiation in patients with HER2-positive salivary gland cancer. The trial aims to establish a treatment protocol for a cancer type lacking FDA-approved therapies.
AI analysis
Indication: Salivary Gland Cancer
Modality: monoclonal antibody
Target: HER2-positive Salivary Gland Carcinomas
Sponsor: Dana-Farber Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: Apr 13, 2026
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Salivary Gland Cancer, HER2 Gene Mutation
Condition normalized: Salivary Gland Cancer, HER2 Gene Mutation
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy
Target normalized: HER2-positive Salivary Gland Carcinomas
NCT02658734Source recordAI-normalized
A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
This study evaluated the safety of trastuzumab emtansine in Indian patients with HER2-positive breast cancer who had prior treatment with trastuzumab and a taxane. Conducted by Hoffmann-La Roche, it involved 70 participants across 13 centers in India.
AI analysis
Indication: HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Modality: monoclonal antibody
Target: HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Apr 02, 2021
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Condition normalized: HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Trastuzumab emtansine
Target normalized: HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
NCT01772472Source recordAI-normalized
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: trastuzumab, trastuzumab emtansine
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Jul 22, 2025
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: trastuzumab, trastuzumab emtansine
Target normalized: trastuzumab, trastuzumab emtansine
NCT01835236Source recordAI-normalized
A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer
This clinical trial evaluates a novel treatment strategy for HER2-positive metastatic breast cancer, comparing a chemotherapy-free regimen of trastuzumab and pertuzumab followed by T-DM1 against a chemotherapy-inclusive regimen. The study aims to determine if the new strategy offers similar or improved efficacy and tolerability compared to standard treatments.
AI analysis
Indication: Metastatic Breast Cancer
Modality: monoclonal antibody
Target: HER2-positive Metastatic Breast Cancer
Sponsor: Swiss Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: Mar 30, 2021
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Metastatic Breast Cancer
Condition normalized: Metastatic Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Trastuzumab, Pertuzumab, Paclitaxel, Vinorelbine, T-DM1
Target normalized: HER2-positive Metastatic Breast Cancer
NCT02144012Source recordAI-normalized
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel as First-Line Treatment of Patients With Her2-Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer.
This terminated clinical trial aimed to evaluate the efficacy and safety of trastuzumab emtansine compared to trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer. The study enrolled only 49 participants out of the planned 561, leading to its termination.
AI analysis
Indication: Metastatic Breast Cancer
Modality: monoclonal antibody
Target: HER2-positive Breast Cancer
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Mar 07, 2017
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Metastatic Breast Cancer
Condition normalized: Metastatic Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Trastuzumab, Trastuzumab Emtansine, Docetaxel
Target normalized: HER2-positive Breast Cancer
NCT00321464Source recordAI-normalized
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer
This clinical trial, sponsored by Amgen and in collaboration with Daiichi Sankyo, aimed to compare the efficacy of Denosumab against Zoledronic Acid in treating bone metastases in patients with advanced breast cancer. The study enrolled 2049 participants and was completed in April 2012.
AI analysis
Indication: Bone Metastases
Modality: monoclonal antibody
Target: Denosumab, Zoledronic Acid
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Nov 08, 2022
Ingested: Jun 04, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Bone Metastases
Condition normalized: Bone Metastases
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab, Zoledronic Acid
Target normalized: Denosumab, Zoledronic Acid
NCT03755193Source recordAI-normalized
Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
This clinical trial, sponsored by Shinshu University, aims to evaluate the efficacy and safety of different anti-resorption drugs (SERM and bisphosphonates) following a 2-year denosumab therapy in Japanese osteoporosis patients. The study is currently recruiting participants and is expected to complete by November 2026.
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug", Bisphosphonates and ELD "Edirol®Tablet 0.75ug", ELD "Edirol®Tablet 0.75ug"
Sponsor: Shinshu University
Source URL: ClinicalTrials.gov
Source updated: Sep 21, 2021
Ingested: Jun 04, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: small molecule
Modality normalized: monoclonal antibody
Target raw: SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug", Bisphosphonates and ELD "Edirol®Tablet 0.75ug", ELD "Edirol®Tablet 0.75ug"
Target normalized: SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug", Bisphosphonates and ELD "Edirol®Tablet 0.75ug", ELD "Edirol®Tablet 0.75ug"
NCT02721433Source recordAI-normalized
A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study
The REaCT-BTA study evaluates the efficacy of 4-weekly versus 12-weekly administration of bone-targeted agents (BTAs) in improving quality of life and reducing skeletal-related events in patients with bone metastases from castration-resistant prostate cancer or breast cancer. The trial was conducted by the Ottawa Hospital Research Institute and completed in April 2020 with 263 enrolled participants.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: Pamidronate, Denosumab, Zoledronate
Sponsor: Ottawa Hospital Research Institute
Source URL: ClinicalTrials.gov
Source updated: Dec 02, 2020
Ingested: Jun 04, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer, Prostate Cancer, Metastasis
Condition normalized: Breast Cancer, Prostate Cancer, Metastasis
Modality raw: small molecule
Modality normalized: monoclonal antibody
Target raw: Pamidronate, Denosumab, Zoledronate
Target normalized: Pamidronate, Denosumab, Zoledronate
NCT06414616Source recordAI-normalized
Are We Overly Concerned About Rebound Fractures? Real-World Evidence of Adherence to Denosumab Therapy and Fracture Risk Associated With Drug Withdrawal: A Cross-sectional Study
This study investigates the adherence to Denosumab therapy and the associated fracture risk upon discontinuation, particularly during the COVID-19 pandemic. It aims to provide real-world evidence on the implications of treatment compliance and the potential rebound effect on fracture risk in osteoporosis patients.
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: Osteoporosis
Sponsor: Trakya University
Source URL: ClinicalTrials.gov
Source updated: May 16, 2024
Ingested: Jun 04, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: Detailed source ingestion pending
Modality normalized: monoclonal antibody
Target raw: Osteoporosis
Target normalized: Osteoporosis
NCT04729621Source recordAI-normalized
A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis
Teva Pharmaceuticals USA conducted a Phase 3 clinical trial (NCT04729621) to evaluate the efficacy and safety of TVB-009P compared to Denosumab (Prolia®) in treating postmenopausal osteoporosis. The study involved 332 participants and was completed in June 2023.
AI analysis
Indication: Osteoporosis, Postmenopausal
Modality: monoclonal antibody
Target: TVB-009, Prolia®
Sponsor: Teva Pharmaceuticals USA
Source URL: ClinicalTrials.gov
Source updated: Apr 18, 2024
Ingested: Jun 04, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis, Postmenopausal
Condition normalized: Osteoporosis, Postmenopausal
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: TVB-009, Prolia®
Target normalized: TVB-009, Prolia®
NCT03651947Source recordAI-normalized
A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
QL1206 is being developed by Qilu Pharmaceutical Co., Ltd. as a biosimilar to Xgeva® (Denosumab), targeting the treatment of conditions related to bone metabolism. The trial aimed to establish pharmacokinetic, safety, and pharmacodynamic similarities between QL1206 and Xgeva® in healthy adults.
AI analysis
Indication: Healthy People
Modality: monoclonal antibody
Target: QL1206, Xgeva®
Sponsor: Qilu Pharmaceutical Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Oct 16, 2019
Ingested: Jun 04, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Healthy People
Condition normalized: Healthy People
Modality raw: small molecule
Modality normalized: monoclonal antibody
Target raw: QL1206, Xgeva®
Target normalized: QL1206, Xgeva®
NCT05395091Source recordAI-normalized
A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopausal Women With Osteoporosis, ALVOBOND
The ALVOBOND study evaluates AVT03, a proposed biosimilar to Prolia (denosumab), in postmenopausal women with osteoporosis. The trial aims to demonstrate comparable efficacy, safety, immunogenicity, and pharmacokinetic profiles between AVT03 and Prolia. The study completed enrollment of 532 participants across multiple countries.
AI analysis
Indication: Osteoporosis, Postmenopausal
Modality: monoclonal antibody
Target: Osteoporosis, Postmenopausal
Sponsor: Alvotech Swiss AG
Source URL: ClinicalTrials.gov
Source updated: May 29, 2025
Ingested: Jun 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis, Postmenopausal
Condition normalized: Osteoporosis, Postmenopausal
Modality raw: Osteoporosis, Postmenopausal
Modality normalized: monoclonal antibody
Target raw: Osteoporosis, Postmenopausal
Target normalized: Osteoporosis, Postmenopausal
NCT07360080Source recordAI-normalized
Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care
Sanofi is conducting a prospective cohort study to evaluate the long-term outcomes of teplizumab treatment in patients with Stage 2 Type 1 Diabetes. The study aims to assess the drug's effectiveness in delaying the onset of Stage 3 T1D and its impact on patients' quality of life through various patient-reported outcomes.
AI analysis
Indication: Type 1 Diabetes
Modality: monoclonal antibody
Target: Type 1 Diabetes (Stage 2)
Sponsor: Sanofi
Source URL: ClinicalTrials.gov
Source updated: May 27, 2026
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Type 1 Diabetes
Condition normalized: Type 1 Diabetes
Modality raw: Type 1 Diabetes
Modality normalized: monoclonal antibody
Target raw: Type 1 Diabetes (Stage 2)
Target normalized: Type 1 Diabetes (Stage 2)
NCT00385697Source recordAI-normalized
A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of MGA031, a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The Protégé Study evaluated MGA031 (teplizumab), a humanized anti-CD3 monoclonal antibody, for its efficacy and safety in reducing insulin requirements and improving blood sugar levels in children and adults with recent-onset type 1 diabetes. Conducted by MacroGenics in collaboration with Eli Lilly, the trial enrolled 554 participants across multiple centers.
AI analysis
Indication: Type 1 Diabetes Mellitus
Modality: monoclonal antibody
Target: Type 1 Diabetes Mellitus
Sponsor: MacroGenics
Source URL: ClinicalTrials.gov
Source updated: Dec 05, 2023
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Type 1 Diabetes Mellitus
Condition normalized: Type 1 Diabetes Mellitus
Modality raw: Type 1 Diabetes Mellitus
Modality normalized: monoclonal antibody
Target raw: Type 1 Diabetes Mellitus
Target normalized: Type 1 Diabetes Mellitus
NCT00239720Source recordAI-normalized
Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)
The clinical trial evaluated the safety and efficacy of hOKT3γ1 (Ala-Ala), a monoclonal antibody targeting CD3 on T cells, in patients with psoriatic arthritis unresponsive to standard therapies. The study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and aimed to provide a new treatment option for patients with severe disease.
AI analysis
Indication: Arthritis, Psoriatic
Modality: monoclonal antibody
Target: Psoriatic Arthritis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Source URL: ClinicalTrials.gov
Source updated: Apr 27, 2017
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Arthritis, Psoriatic
Condition normalized: Arthritis, Psoriatic
Modality raw: Arthritis, Psoriatic
Modality normalized: monoclonal antibody
Target raw: Psoriatic Arthritis
Target normalized: Psoriatic Arthritis
NCT03751007Source recordAI-normalized
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
The clinical trial assessed the safety and tolerability of AG019, both as a monotherapy and in combination with Teplizumab, in patients with recent-onset Type 1 Diabetes. Conducted by Precigen Actobio T1D, LLC, the study aimed to evaluate different dosing regimens across two age groups (12-17 and 18-40 years).
AI analysis
Indication: Diabetes type1
Modality: monoclonal antibody
Target: Type 1 Diabetes (T1D)
Sponsor: Precigen Actobio T1D, LLC
Source URL: ClinicalTrials.gov
Source updated: Feb 01, 2023
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Diabetes type1
Condition normalized: Diabetes type1
Modality raw: Diabetes type1
Modality normalized: monoclonal antibody
Target raw: Type 1 Diabetes (T1D)
Target normalized: Type 1 Diabetes (T1D)
NCT00870818Source recordAI-normalized
An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus
The study aimed to evaluate the long-term safety and efficacy of Teplizumab (MGA031), a monoclonal antibody, in patients with recent-onset Type 1 Diabetes Mellitus. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company. It was terminated due to a business decision after enrolling 219 participants.
AI analysis
Indication: Type 1 Diabetes Mellitus
Modality: monoclonal antibody
Target: Type 1 Diabetes Mellitus
Sponsor: MacroGenics
Source URL: ClinicalTrials.gov
Source updated: Aug 09, 2023
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Type 1 Diabetes Mellitus
Condition normalized: Type 1 Diabetes Mellitus
Modality raw: Type 1 Diabetes Mellitus
Modality normalized: monoclonal antibody
Target raw: Type 1 Diabetes Mellitus
Target normalized: Type 1 Diabetes Mellitus
NCT00954915Source recordAI-normalized
A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis
The study aimed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of teplizumab, a monoclonal antibody, in adults with moderate to severe psoriasis. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company.
AI analysis
Indication: Psoriasis
Modality: monoclonal antibody
Target: Psoriasis
Sponsor: MacroGenics
Source URL: ClinicalTrials.gov
Source updated: Feb 10, 2022
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Psoriasis
Condition normalized: Psoriasis
Modality raw: Psoriasis
Modality normalized: monoclonal antibody
Target raw: Psoriasis
Target normalized: Psoriasis
NCT03875729Source recordAI-normalized
Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized Fc Receptor (FcR) Non-Binding Anti-cluster of Differentiation 3 (CD3) Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes
Provention Bio, Inc. conducted a Phase 3 trial to evaluate the efficacy and safety of teplizumab, a humanized anti-CD3 monoclonal antibody, in children and adolescents aged 8-17 with recent-onset Type 1 Diabetes (T1D). The study aimed to preserve β cell function and slow the loss of β cells over 18 months.
AI analysis
Indication: Type 1 Diabetes Mellitus
Modality: monoclonal antibody
Target: Type 1 Diabetes Mellitus
Sponsor: Provention Bio, Inc.
Source URL: ClinicalTrials.gov
Source updated: Apr 24, 2024
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Type 1 Diabetes Mellitus
Condition normalized: Type 1 Diabetes Mellitus
Modality raw: Type 1 Diabetes Mellitus
Modality normalized: monoclonal antibody
Target raw: Type 1 Diabetes Mellitus
Target normalized: Type 1 Diabetes Mellitus
NCT03867084Source recordAI-normalized
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)
This clinical trial evaluates the safety and efficacy of pembrolizumab (MK-3475) as adjuvant therapy in patients with HCC who have achieved complete radiological response following surgical resection or local ablation. The study aims to demonstrate superiority in recurrence-free survival (RFS) and overall survival (OS) compared to placebo.
AI analysis
Indication: Hepatocellular Carcinoma
Modality: monoclonal antibody
Target: Hepatocellular Carcinoma (HCC)
Sponsor: Merck Sharp & Dohme LLC
Source URL: ClinicalTrials.gov
Source updated: Apr 24, 2026
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Hepatocellular Carcinoma
Condition normalized: Hepatocellular Carcinoma
Modality raw: Hepatocellular Carcinoma
Modality normalized: monoclonal antibody
Target raw: Hepatocellular Carcinoma (HCC)
Target normalized: Hepatocellular Carcinoma (HCC)
NCT01055314Source recordAI-normalized
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma
This pilot study evaluated the feasibility and efficacy of combining temozolomide and cixutumumab with a multi-agent chemotherapy regimen for high-risk metastatic rhabdomyosarcoma in children and adults. The study was sponsored by the National Cancer Institute and involved 175 participants.
AI analysis
Indication: Adult Rhabdomyosarcoma
Modality: monoclonal antibody
Target: Metastatic Rhabdomyosarcoma
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Aug 29, 2017
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Adult Rhabdomyosarcoma
Condition normalized: Adult Rhabdomyosarcoma
Modality raw: Adult Rhabdomyosarcoma
Modality normalized: monoclonal antibody
Target raw: Metastatic Rhabdomyosarcoma
Target normalized: Metastatic Rhabdomyosarcoma
NCT00687882Source recordAI-normalized
Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children
The Kids-DOTT trial evaluates the non-inferiority of a shortened duration (6 weeks) versus conventional duration (3 months) of anticoagulation therapy in children with first-episode acute venous thrombosis. The study aims to enroll 750 children across 40 centers, focusing on safety and efficacy outcomes related to recurrent venous thromboembolism (VTE) and bleeding.
AI analysis
Indication: Venous Thrombosis
Modality: monoclonal antibody
Target: Venous Thrombosis in Children
Sponsor: Johns Hopkins All Children's Hospital
Source URL: ClinicalTrials.gov
Source updated: Jun 18, 2025
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Venous Thrombosis
Condition normalized: Venous Thrombosis
Modality raw: Venous Thrombosis
Modality normalized: monoclonal antibody
Target raw: Venous Thrombosis in Children
Target normalized: Venous Thrombosis in Children
NCT03518320Source recordAI-normalized
A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
The clinical trial investigated the safety and tolerability of TAR-200, a drug delivery system, in combination with Nivolumab for patients with muscle-invasive bladder cancer (MIBC) scheduled for radical cystectomy. The study was sponsored by Taris Biomedical LLC in collaboration with Bristol-Myers Squibb.
AI analysis
Indication: Bladder Cancer TNM Staging Primary Tumor (T) T2
Modality: monoclonal antibody
Target: Muscle-Invasive Bladder Cancer
Sponsor: Taris Biomedical LLC
Source URL: ClinicalTrials.gov
Source updated: Aug 27, 2024
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Bladder Cancer TNM Staging Primary Tumor (T) T2
Condition normalized: Bladder Cancer TNM Staging Primary Tumor (T) T2
Modality raw: Bladder Cancer TNM Staging Primary Tumor (T) T2
Modality normalized: monoclonal antibody
Target raw: Muscle-Invasive Bladder Cancer
Target normalized: Muscle-Invasive Bladder Cancer
NCT05757713Source recordAI-normalized
Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants <8 Years of Age With at Least Two Autoantibodies and Dysglycemia)
Sanofi is conducting a single-arm, open-label clinical trial to evaluate the safety and pharmacokinetics of teplizumab in pediatric patients under 8 years of age with Stage 2 Type 1 Diabetes. The study aims to enroll approximately 20 participants and will assess treatment-emergent adverse events, pharmacokinetics, and immunogenicity over a period of up to 26 months.
AI analysis
Indication: Diabetes Mellitus, Type 1
Modality: monoclonal antibody
Target: Type 1 Diabetes (Stage 2)
Sponsor: Sanofi
Source URL: ClinicalTrials.gov
Source updated: Jan 30, 2026
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Diabetes Mellitus, Type 1
Condition normalized: Diabetes Mellitus, Type 1
Modality raw: Diabetes Mellitus, Type 1
Modality normalized: monoclonal antibody
Target raw: Type 1 Diabetes (Stage 2)
Target normalized: Type 1 Diabetes (Stage 2)
NCT04936308Source recordAI-normalized
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent
This clinical trial evaluates the efficacy and safety of Guselkumab in patients with active psoriatic arthritis who have had an inadequate response or intolerance to one prior anti-TNF alpha agent. The study is sponsored by Janssen Research & Development, LLC and aims to establish Guselkumab as a viable treatment option in this patient population.
AI analysis
Indication: Arthritis, Psoriatic
Modality: monoclonal antibody
Target: Guselkumab
Sponsor: Janssen Research & Development, LLC
Source URL: ClinicalTrials.gov
Source updated: May 08, 2026
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Arthritis, Psoriatic
Condition normalized: Arthritis, Psoriatic
Modality raw: Arthritis, Psoriatic
Modality normalized: monoclonal antibody
Target raw: Guselkumab
Target normalized: Guselkumab
NCT04338529Source recordAI-normalized
Alendronate in an Weekly Effervescent Tablet Formulation for Preservation of Bone Mass After Denosumab Discontinuation in Postmenopausal Women with Low Bone Mass. an Observational Study (Binosto After Denosumab - the BAD Study)
This study investigates the efficacy of transitioning from denosumab to oral alendronate in a weekly effervescent tablet formulation for preserving bone mineral density (BMD) in postmenopausal women with low bone mass. The study aims to provide insights into optimal treatment duration and management strategies following denosumab discontinuation.
AI analysis
Indication: Postmenopausal Osteoporosis
Modality: monoclonal antibody
Target: Postmenopausal Osteoporosis
Sponsor: 251 Hellenic Air Force & VA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Dec 02, 2024
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Postmenopausal Osteoporosis
Condition normalized: Postmenopausal Osteoporosis
Modality raw: Postmenopausal Osteoporosis
Modality normalized: monoclonal antibody
Target raw: Postmenopausal Osteoporosis
Target normalized: Postmenopausal Osteoporosis
NCT05366621Source recordAI-normalized
The Association Between Anti-osteoporosis Medications and Lowered All Cause Mortality After Osteoporotic Fractures
This observational study aimed to assess the relationship between anti-osteoporosis medications and all-cause mortality in older adults following osteoporotic fractures. Conducted by National Cheng-Kung University Hospital, it involved a cohort of 216,155 participants and spanned a 12-year observation period.
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: Osteoporosis and Mortality
Sponsor: National Cheng-Kung University Hospital
Source URL: ClinicalTrials.gov
Source updated: Apr 04, 2023
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: Osteoporosis
Modality normalized: monoclonal antibody
Target raw: Osteoporosis and Mortality
Target normalized: Osteoporosis and Mortality
NCT06076772Source recordAI-normalized
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
This study aims to assess the risk factors and treatment outcomes associated with neutropenia induced by Palbociclib in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study will evaluate progression-free survival (PFS) and overall survival (OS) over a two-year period, providing insights into the pharmacodynamics of Palbociclib and potential dose optimization strategies.
AI analysis
Indication: Metastatic Breast Cancer
Modality: monoclonal antibody
Target: Palbociclib-induced neutropenia in metastatic breast cancer patients
Sponsor: Assiut University
Source URL: ClinicalTrials.gov
Source updated: Oct 11, 2023
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Metastatic Breast Cancer
Condition normalized: Metastatic Breast Cancer
Modality raw: Metastatic Breast Cancer
Modality normalized: monoclonal antibody
Target raw: Palbociclib-induced neutropenia in metastatic breast cancer patients
Target normalized: Palbociclib-induced neutropenia in metastatic breast cancer patients
NCT01572545Source recordAI-normalized
Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial
This completed clinical trial compared the effects of Zoledronic Acid and Denosumab on serum sclerostin levels, a key biomarker in bone metabolism, in postmenopausal women with low bone mass. The study aimed to provide insights into the efficacy of these two leading osteoporosis treatments.
AI analysis
Indication: Postmenopausal Osteoporosis
Modality: monoclonal antibody
Target: Serum sclerostin levels in postmenopausal women with low bone mass
Sponsor: Aristotle University Of Thessaloniki
Source URL: ClinicalTrials.gov
Source updated: Jan 17, 2013
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Postmenopausal Osteoporosis
Condition normalized: Postmenopausal Osteoporosis
Modality raw: Postmenopausal Osteoporosis
Modality normalized: monoclonal antibody
Target raw: Serum sclerostin levels in postmenopausal women with low bone mass
Target normalized: Serum sclerostin levels in postmenopausal women with low bone mass
NCT06272227Source recordAI-normalized
Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial
This clinical trial, sponsored by Yonsei University, aims to evaluate the efficacy of alfacalcidol in enhancing muscle function in postmenopausal women with osteoporosis and functional sarcopenia. The study will involve 340 participants over a one-year period, comparing outcomes between the alfacalcidol and placebo groups.
AI analysis
Indication: Sarcopenia
Modality: monoclonal antibody
Target: Muscle function improvement in osteoporosis patients
Sponsor: Yonsei University
Source URL: ClinicalTrials.gov
Source updated: Feb 22, 2024
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Sarcopenia
Condition normalized: Sarcopenia
Modality raw: Sarcopenia
Modality normalized: monoclonal antibody
Target raw: Muscle function improvement in osteoporosis patients
Target normalized: Muscle function improvement in osteoporosis patients
NCT05389462Source recordAI-normalized
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A. initiated a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumors, particularly focusing on sarcomas and pancreatic cancer. The study aimed to establish the recommended phase 2 dose and assess the drug's efficacy in combination with gemcitabine.
AI analysis
Indication: Advanced Solid Tumors
Modality: monoclonal antibody
Target: Mipasetamab Uzoptirine (ADCT-601)
Sponsor: ADC Therapeutics S.A.
Source URL: ClinicalTrials.gov
Source updated: May 22, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Advanced Solid Tumors
Condition normalized: Advanced Solid Tumors
Modality raw: Advanced Solid Tumors
Modality normalized: monoclonal antibody
Target raw: Mipasetamab Uzoptirine (ADCT-601)
Target normalized: Mipasetamab Uzoptirine (ADCT-601)
NCT05353179Source recordAI-normalized
Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is conducting a Phase I clinical trial to evaluate the pharmacokinetics and safety of Meperizumab injection compared to NUCALA® in healthy male volunteers. The study aims to enroll 88 subjects and assess the similarity in drug behavior and safety profiles.
AI analysis
Indication: Granulomatosis With Polyangiitis
Modality: monoclonal antibody
Target: Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Apr 29, 2022
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Granulomatosis With Polyangiitis
Condition normalized: Granulomatosis With Polyangiitis
Modality raw: Granulomatosis With Polyangiitis
Modality normalized: monoclonal antibody
Target raw: Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)
Target normalized: Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)
NCT02658084Source recordAI-normalized
A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: Vinorelbine, Trastuzumab Emtansine
Sponsor: University of Miami
Source URL: ClinicalTrials.gov
Source updated: Apr 17, 2019
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: Breast Cancer
Modality normalized: monoclonal antibody
Target raw: Vinorelbine, Trastuzumab Emtansine
Target normalized: Vinorelbine, Trastuzumab Emtansine
NCT06663787Source recordAI-normalized
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment
This clinical trial aims to evaluate the status of circulating tumor DNA (ctDNA) in patients with HER2-positive metastatic breast cancer who have achieved a durable response to anti-HER2 treatment. The study utilizes the Signatera™ ctDNA assay to assess minimal residual disease (MRD) and explore potential new therapeutic strategies, including the possibility of de-escalating treatment in ctDNA-negative patients.
AI analysis
Indication: Breast Cancer, Metastatic
Modality: monoclonal antibody
Target: HER2-positive metastatic breast cancer
Sponsor: Nagoya City University
Source URL: ClinicalTrials.gov
Source updated: May 13, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer, Metastatic, HER2 + Breast Cancer
Condition normalized: Breast Cancer, Metastatic, HER2 + Breast Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Trastuzumab (Herceptin), SIgnatera
Target normalized: HER2-positive metastatic breast cancer
NCT03878524Source recordAI-normalized
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
AI analysis
Indication: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Modality: monoclonal antibody
Target: Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Sponsor: OHSU Knight Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: Mar 04, 2024
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Condition normalized: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Modality raw: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Modality normalized: monoclonal antibody
Target raw: Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Target normalized: Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
NCT01513083Source recordAI-normalized
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
This open-label, parallel group study will evaluate the pharmacokinetics and safety of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function. Patients will receive trastuzumab emtansine intravenously on Day 1 of each 3-week cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: trastuzumab emtansine
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Nov 02, 2016
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: Breast Cancer
Modality normalized: monoclonal antibody
Target raw: trastuzumab emtansine
Target normalized: trastuzumab emtansine
NCT01853748Source recordAI-normalized
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA has not approved this drug for use patients undergoing adjuvant treatment for HER2+ breast cancer. Trastuzumab emtansine (T-DM1) is a drug that may stop cancer cells from growing. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to prevent the recurrence of breast cancer in this research study. The use of T-DM1 in this research study is experimental, which means it is not approved by any regulatory authority for the adjuvant treatment of HER2-positive breast cancer. However, it FDA-approved for metastatic HER2-positive breast cancer. T-DM1 has caused cancer cells to die in laboratory studies. In preclinical studies, this drug has prevented or slowed the growth of breast cancer. The breast cancer treatments (paclitaxel and Trastuzumab) used in this study are considered part of standard-of-care regimens in early breast cancer. A standard treatment means that this is a treatment that would be accepted by the majority of the medical community as a suitable treatment for your type of breast cancer. In this research study, the investigators are looking to see if the study drug T-DM1 will have less side effects than traditional HER2-positive breast cancer treatment of trastuzumab and paclitaxel. The investigators are also hoping to learn about the long term benefits and disease-free survival of participants who take the study drug T-DM1 in comparison to those participants to take the combination of trastuzumab and paclitaxel.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Sponsor: Dana-Farber Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: Feb 19, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: Breast Cancer
Modality normalized: monoclonal antibody
Target raw: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Target normalized: Trastuzumab, Paclitaxel, Trastuzumab emtansine
NCT00679341Source recordAI-normalized
A Randomized, Multicenter, Phase ii Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
This was a Phase II, randomized, multicenter, international, 2-arm, open-label clinical trial designed to explore the efficacy and safety of trastuzumab emtansine (T-DM1) relative to the combination of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced breast cancer and/or metastatic breast cancer who have not received prior chemotherapy for metastatic disease.
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: Trastuzumab emtansine [Kadcyla], Trastuzumab, Docetaxel
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Jan 09, 2014
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: Breast Cancer
Modality normalized: monoclonal antibody
Target raw: Trastuzumab emtansine [Kadcyla], Trastuzumab, Docetaxel
Target normalized: Trastuzumab emtansine [Kadcyla], Trastuzumab, Docetaxel
NCT04769050Source recordAI-normalized
A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment
Dynamic observationaL study with PET of 68Ga-HER2-affibody in anti-HER2 treatment
AI analysis
Indication: Breast Cancer
Modality: monoclonal antibody
Target: Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.
Sponsor: Fudan University
Source URL: ClinicalTrials.gov
Source updated: Apr 20, 2022
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: Breast Cancer
Modality normalized: monoclonal antibody
Target raw: Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.
Target normalized: Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.
NCT01745757Source recordAI-normalized
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer
The COMET study, sponsored by UNICANCER, aimed to validate predictive factors and biological imaging related to the response of metastatic breast cancer patients to Bevacizumab and Paclitaxel. The study enrolled 510 patients and was completed in December 2022. It focused on identifying biomarkers that could help tailor treatments and improve patient outcomes.
AI analysis
Indication: Metastatic
Modality: monoclonal antibody
Target: Metastatic Breast Cancer
Sponsor: UNICANCER
Source URL: ClinicalTrials.gov
Source updated: Jan 27, 2023
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Metastatic
Condition normalized: Metastatic
Modality raw: Metastatic
Modality normalized: monoclonal antibody
Target raw: Metastatic Breast Cancer
Target normalized: Metastatic Breast Cancer
NCT05502341Source recordAI-normalized
An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens
This clinical trial, sponsored by Gilead Sciences, aims to evaluate the safety and efficacy of Bictegravir (BIC) and Lenacapavir (LEN) compared to current therapies in patients with HIV-1 who are virologically suppressed on complex treatment regimens. The study is designed as a randomized, open-label, multicenter trial with a total enrollment of 689 participants.
AI analysis
Indication: HIV-1-infection
Modality: monoclonal antibody
Target: HIV-1 infection
Sponsor: Gilead Sciences
Source URL: ClinicalTrials.gov
Source updated: Oct 14, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: HIV-1-infection
Condition normalized: HIV-1-infection
Modality raw: HIV-1-infection
Modality normalized: monoclonal antibody
Target raw: HIV-1 infection
Target normalized: HIV-1 infection
NCT04170283Source recordAI-normalized
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
This long-term extension study evaluates the safety and efficacy of zanubrutinib (BGB-3111) in patients with B-cell malignancies who have previously participated in a parent study. The study aims to provide insights into the long-term effects and potential benefits of continued treatment with zanubrutinib, either alone or in combination with Tislelizumab.
AI analysis
Indication: B-cell Malignancies
Modality: monoclonal antibody
Target: B-cell Malignancies
Sponsor: BeiGene
Source URL: ClinicalTrials.gov
Source updated: Oct 21, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: B-cell Malignancies
Condition normalized: B-cell Malignancies
Modality raw: B-cell Malignancies
Modality normalized: monoclonal antibody
Target raw: B-cell Malignancies
Target normalized: B-cell Malignancies
NCT01652690Source recordAI-normalized
Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice
This study aimed to characterize the management of postmenopausal osteoporosis patients treated with denosumab in routine clinical practice across the Czech Republic and Slovakia. It involved 600 participants and focused on treatment adherence and safety data over a 24-month period.
AI analysis
Indication: Osteoporosis, Postmenopausal
Modality: monoclonal antibody
Target: Denosumab (Prolia®)
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Mar 06, 2019
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis, Postmenopausal
Condition normalized: Osteoporosis, Postmenopausal
Modality raw: Osteoporosis, Postmenopausal
Modality normalized: monoclonal antibody
Target raw: Denosumab (Prolia®)
Target normalized: Denosumab (Prolia®)
NCT02299817Source recordAI-normalized
Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography
This clinical trial investigates the efficacy of denosumab in reducing wear-induced osteolysis around uncemented acetabular implants in total hip arthroplasty. The study aims to provide insights into the potential of denosumab as a treatment option for patients experiencing osteolysis post-surgery.
AI analysis
Indication: Osteolysis
Modality: monoclonal antibody
Target: Osteolysis
Sponsor: Olof Skoldenberg
Source URL: ClinicalTrials.gov
Source updated: Feb 07, 2019
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteolysis
Condition normalized: Osteolysis
Modality raw: Osteolysis
Modality normalized: monoclonal antibody
Target raw: Osteolysis
Target normalized: Osteolysis
NCT01799798Source recordAI-normalized
TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA - A PILOT TRIAL ON TREATMENT WITH THE RANKL-ANTIBODY DENOSUMAB
This pilot trial evaluated the efficacy of Denosumab, a RANKL antibody, in treating children aged 5-10 with Osteogenesis Imperfecta caused by COL1A1 or COL1A2 mutations. The study aimed to assess changes in bone mineral density (BMD) after 36 weeks of treatment.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: monoclonal antibody
Target: Osteogenesis Imperfecta
Sponsor: University of Cologne
Source URL: ClinicalTrials.gov
Source updated: Jan 27, 2015
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: Osteogenesis Imperfecta
Modality normalized: monoclonal antibody
Target raw: Osteogenesis Imperfecta
Target normalized: Osteogenesis Imperfecta
NCT05876949Source recordAI-normalized
A Randomized, Double-blind, Parallel Design, Single Dose, 2-arm Study Comparing the Pharmacokinetic, Safety and Immunogenicity Profiles of AVT03 and US-Xgeva® in Healthy Male Subjects
AVT03 is a proposed biosimilar to Xgeva (denosumab), developed by Alvotech Swiss AG. The clinical trial aimed to compare the pharmacokinetic, safety, and immunogenicity profiles of AVT03 against the reference product in healthy male subjects aged 28 to 55. The study was completed with a total enrollment of 208 participants.
AI analysis
Indication: This is a Phase I Study Conducted in Healthy Volunteers
Modality: monoclonal antibody
Target: AVT03 (biosimilar to Denosumab)
Sponsor: Alvotech Swiss AG
Source URL: ClinicalTrials.gov
Source updated: May 15, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: This is a Phase I Study Conducted in Healthy Volunteers
Condition normalized: This is a Phase I Study Conducted in Healthy Volunteers
Modality raw: This is a Phase I Study Conducted in Healthy Volunteers
Modality normalized: monoclonal antibody
Target raw: AVT03 (biosimilar to Denosumab)
Target normalized: AVT03 (biosimilar to Denosumab)
NCT02239523Source recordAI-normalized
Management Strategies by an Orthopedic Department to Improve the Evaluation and Treatment of Osteoporosis.
This clinical trial evaluates the effectiveness of orthopedic interventions in managing osteoporosis in patients with fragility fractures. It aims to improve treatment adherence and conduct a cost-benefit analysis of the interventions. The study was conducted at Shaare Zedek Medical Center and involved 200 patients over 50 years old.
AI analysis
Indication: Osteoporotic Fracture
Modality: monoclonal antibody
Target: Osteoporosis management after hip fracture
Sponsor: Shaare Zedek Medical Center
Source URL: ClinicalTrials.gov
Source updated: Apr 05, 2019
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporotic Fracture
Condition normalized: Osteoporotic Fracture
Modality raw: Osteoporotic Fracture
Modality normalized: monoclonal antibody
Target raw: Osteoporosis management after hip fracture
Target normalized: Osteoporosis management after hip fracture
NCT03174366Source recordAI-normalized
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to below-knee amputation of the affected limb. Currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. The purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage Charcot neuroarthropathy.
AI analysis
Indication: Charcot Joint of Foot
Modality: monoclonal antibody
Target: Denosumab
Sponsor: Western University of Health Sciences
Source URL: ClinicalTrials.gov
Source updated: Oct 23, 2019
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Charcot Joint of Foot
Condition normalized: Charcot Joint of Foot
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Denosumab
Target normalized: Denosumab
NCT00089791Source recordAI-normalized
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
The FREEDOM trial evaluated the efficacy and safety of Denosumab, a monoclonal antibody, in reducing fractures in postmenopausal women with osteoporosis. Conducted by Amgen, the study enrolled 7,808 participants and demonstrated significant fracture risk reduction, positioning Denosumab as a competitive treatment option in the osteoporosis market.
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: Postmenopausal Osteoporosis
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Nov 08, 2022
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: Osteoporosis
Modality normalized: monoclonal antibody
Target raw: Postmenopausal Osteoporosis
Target normalized: Postmenopausal Osteoporosis
NCT05299073Source recordAI-normalized
A Randomised, Double-blind, Three-arm, Single-dose, Parallel Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Profile of MB09 (Denosumab Biosimilar) and EU/US-sourced Xgeva® in Healthy Male Volunteers
The clinical trial evaluated the pharmacokinetic (PK) similarity, pharmacodynamics (PD), safety, and immunogenicity of MB09, a biosimilar to Xgeva, in healthy male volunteers. The study was conducted by mAbxience Research S.L. and involved 257 participants across three arms: MB09, US-sourced Xgeva, and EU-sourced Xgeva.
AI analysis
Indication: Healthy Volunteers
Modality: monoclonal antibody
Target: Denosumab Biosimilar (MB09)
Sponsor: mAbxience Research S.L.
Source URL: ClinicalTrials.gov
Source updated: Jan 03, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Healthy Volunteers
Condition normalized: Healthy Volunteers
Modality raw: Healthy Volunteers
Modality normalized: monoclonal antibody
Target raw: Denosumab Biosimilar (MB09)
Target normalized: Denosumab Biosimilar (MB09)
NCT03869762Source recordAI-normalized
A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
The DICE trial investigated the combination of Denosumab and Enzalutamide in patients with progressive metastatic castration-resistant prostate cancer and bone metastases. The study was terminated due to insufficient patient accrual, with only 7 participants enrolled.
AI analysis
Indication: Castration-resistant Prostate Cancer
Modality: monoclonal antibody
Target: Castration-resistant Prostate Cancer
Sponsor: Cancer Trials Ireland
Source URL: ClinicalTrials.gov
Source updated: Apr 13, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Castration-resistant Prostate Cancer
Condition normalized: Castration-resistant Prostate Cancer
Modality raw: Castration-resistant Prostate Cancer
Modality normalized: monoclonal antibody
Target raw: Castration-resistant Prostate Cancer
Target normalized: Castration-resistant Prostate Cancer
NCT03401060Source recordAI-normalized
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
This clinical trial evaluates the efficacy of Denosumab, an anti-RANKL monoclonal antibody, in improving bone mineral density (BMD) in patients with osteoporosis due to systemic mastocytosis. The study is sponsored by Assistance Publique - Hôpitaux de Paris and involves a randomized, double-blind design comparing Denosumab to a placebo over three years.
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: Osteoporosis associated with systemic mastocytosis
Sponsor: Assistance Publique - Hôpitaux de Paris
Source URL: ClinicalTrials.gov
Source updated: Mar 31, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: Osteoporosis
Modality normalized: monoclonal antibody
Target raw: Osteoporosis associated with systemic mastocytosis
Target normalized: Osteoporosis associated with systemic mastocytosis
NCT04241211Source recordAI-normalized
Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial
This clinical trial investigates the efficacy of Teriparatide (Forsteo) compared to Denosumab (Prolia) in reducing the incidence of Proximal Junctional Kyphosis (PJK) following Adult Spinal Deformity (ASD) surgery. The study is being conducted at Seoul National University Bundang Hospital and aims to provide insights into effective medical therapies for PJK prevention.
AI analysis
Indication: Spine Deformity
Modality: monoclonal antibody
Target: Proximal Junctional Kyphosis (PJK)
Sponsor: Seoul National University Bundang Hospital
Source URL: ClinicalTrials.gov
Source updated: Jan 27, 2020
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Spine Deformity
Condition normalized: Spine Deformity
Modality raw: Spine Deformity
Modality normalized: monoclonal antibody
Target raw: Proximal Junctional Kyphosis (PJK)
Target normalized: Proximal Junctional Kyphosis (PJK)
NCT06154707Source recordAI-normalized
Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes
This clinical trial aims to evaluate the efficacy of Denosumab in treating osteoporosis and its impact on sarcopenia in a domestic population. The study involves a randomized controlled design with an estimated enrollment of 86 participants, comparing Denosumab treatment against a placebo over a 12-month period.
AI analysis
Indication: Sarcopenia
Modality: monoclonal antibody
Target: Osteoporosis and Sarcopenia
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Source URL: ClinicalTrials.gov
Source updated: Aug 16, 2024
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Sarcopenia
Condition normalized: Sarcopenia
Modality raw: Sarcopenia
Modality normalized: monoclonal antibody
Target raw: Osteoporosis and Sarcopenia
Target normalized: Osteoporosis and Sarcopenia
NCT02682693Source recordAI-normalized
Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)
The GeparX trial investigated denosumab as an adjunct to neoadjuvant chemotherapy in patients with RANK-positive breast cancer. Conducted by GBG Forschungs GmbH in collaboration with Amgen and Celgene, the study aimed to enhance pathological complete response (pCR) rates and improve patient outcomes. The trial enrolled 780 participants and was completed in December 2020.
AI analysis
Indication: Breast Cancer Female NOS
Modality: monoclonal antibody
Target: RANK-positive or RANK-negative Primary Breast Cancer
Sponsor: GBG Forschungs GmbH
Source URL: ClinicalTrials.gov
Source updated: Feb 02, 2021
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Breast Cancer Female NOS
Condition normalized: Breast Cancer Female NOS
Modality raw: Breast Cancer Female NOS
Modality normalized: monoclonal antibody
Target raw: RANK-positive or RANK-negative Primary Breast Cancer
Target normalized: RANK-positive or RANK-negative Primary Breast Cancer
NCT04467983Source recordAI-normalized
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
This clinical trial evaluates the efficacy of adding abaloparatide to ongoing denosumab treatment in postmenopausal women with osteoporosis. The study aims to determine if this combination therapy can improve bone mineral density (BMD) compared to continued denosumab alone. The trial is sponsored by the Hospital for Special Surgery in New York, with collaboration from Radius Health, Inc.
AI analysis
Indication: Osteoporosis, Postmenopausal
Modality: monoclonal antibody
Target: Osteoporosis, Postmenopausal
Sponsor: Hospital for Special Surgery, New York
Source URL: ClinicalTrials.gov
Source updated: May 02, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis, Postmenopausal
Condition normalized: Osteoporosis, Postmenopausal
Modality raw: Osteoporosis, Postmenopausal
Modality normalized: monoclonal antibody
Target raw: Osteoporosis, Postmenopausal
Target normalized: Osteoporosis, Postmenopausal
NCT02166437Source recordAI-normalized
Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study
This clinical trial investigates the efficacy of bisphosphonate and denosumab therapies following teriparatide treatment in Japanese patients with severe osteoporosis. The study aims to analyze bone mineral density (BMD), bone turnover markers, and fracture prevention effects in a cohort of 500 patients.
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: Osteoporosis
Sponsor: Tomidahama Hospital
Source URL: ClinicalTrials.gov
Source updated: Oct 19, 2016
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: Osteoporosis
Modality normalized: monoclonal antibody
Target raw: Osteoporosis
Target normalized: Osteoporosis
NCT02435147Source recordAI-normalized
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
This study evaluated the long-term effects of denosumab on trabecular bone score (TBS) and femur strength index (FSI) in postmenopausal women with osteoporosis. Conducted by HealthEast Care System, the observational study involved 86 participants, with 75 completing the study. The findings support denosumab's role in improving bone health metrics over 36 months.
AI analysis
Indication: Osteoporosis
Modality: monoclonal antibody
Target: denosumab
Sponsor: HealthEast Care System
Source URL: ClinicalTrials.gov
Source updated: Oct 29, 2018
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: monoclonal antibody
View original source fields
Condition raw: Osteoporosis, Bone Fracture
Condition normalized: Osteoporosis, Bone Fracture
Modality raw: small molecule
Modality normalized: monoclonal antibody
Target raw: denosumab
Target normalized: denosumab